Nature CancerImmunologyPeer-reviewed journal article
Dendritic cells accelerate CAR T cells in irradiated tumors through chimeric synapses
Sammy NavarreiD, Maki Ishibashi, Achuth NairiD, Ivan Reyes-TorresiD, Meriem BelabediD, László HalásziD, Matthew D. ParkiD, Raphaël MattiuziD, Merouane Ounadjela, Gertrude GunsetiD, Jorge Mansilla‐SotoiD, Judith FeuchtiD, Annalisa CabrioluiD, Jessica Le BéricheliD, Alexander BirbrairiD, Justin EyquemiD, Brian D. BrowniD, Miriam MéradiD, Michel SadelainiD, Jalal Uddin AhmediD
Abstract
The persistence of adoptively transferred T cells is vital for anti-tumor efficacy. Chimeric antigen receptor (CAR) T cells can persist indefinitely when delivered to patients with B cell cancers and can confer long-term remission. For patients with solid tumors, however, sustaining CAR T cell activity remains a major challenge. This has been attributed in part to the immune microenvironment within solid tumors, though the contribution of specific immune subsets to resistance to CAR T cells is not clear. Here we resolve how the immunology of irradiated tumors dramatically enhances persistence and efficacy of CAR T cells targeted to advanced lung metastases in a syngeneic mouse model. Remarkably, CAR T cell persistence depended critically on dendritic cells (DC) that underwent trogocytic "antigen-dressing" of tumor target antigens and stimulated CAR T cells through the chimeric receptor. Furthermore, tumor irradiation increased antigen-dressing onto DCs. In the absence of functional DCs, CAR T cell activity in irradiated tumor was short-lived and tumors relapsed. These findings establish a critical mechanism through which DCs maintain the CAR T cell pool in irradiated tumors, thus supporting translation of this approach to advance CAR T cell therapy for solid tumors.
- organism: mouse
- assay: CITE-seq
- assay: flow cytometry
- research focus: host-pathogen & immune response
- research focus: cell signaling & trafficking
- research focus: drug response / drug discovery
- approach: experimental assay
- Citations
- 5
- FWCI
- 12.97
- Field percentile
- top 1%
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- CTLA-4 tail fusion enhances CAR-T anti-tumor immunity
- Eradication of tumors with pre-existing antigenic heterogeneity by vaccine-mediated co-engagement of CAR T and endogenous T-cells
L. Ma, D. M. Morgan, … D. J. Irvine·bioRxiv·Oct 5, 2022
- IL-7 armed binary CAR T cell strategy to augment potency against solid tumors
Alejandro G. Torres Chavez, Mary Kathryn McKenna, … Pradip Bajgain·Frontiers in ImmunologyPeer-reviewed·Jul 30, 2025
- Preconditioning Matters: Enhancing or Impairing Antitumor Immunity with DC Vaccines
Eric Kwon, Shelby L. Namen, … Carl J. DeSelm·bioRxiv·May 2, 2025
- Successful dendritic cell vaccines require lasting in-situ TNF α secretion to license antitumor CD8 + T cell cytotoxicity
Nadine Santana-Magal, Aseel Khateeb, … Yaron Carmi·bioRxiv·Apr 8, 2026
- IL-9 signaling redirects CAR T cell fate toward CD8+ memory and CD4+ cycling states, enhancing anti-tumor efficacy
Sofía Castelli, Wesley V. Wilson, … Carl H. June·ImmunityPeer-reviewed·Nov 21, 2025